Hillman Angela R, Chrismas Bryna C R
School of Applied Health Sciences and Wellness, Division of Exercise Physiology, Ohio University, Athens, OH, United States.
College of Education, Department of Physical Education, Qatar University, Doha, Qatar.
Front Nutr. 2021 Sep 16;8:733057. doi: 10.3389/fnut.2021.733057. eCollection 2021.
Tart cherries possess properties that may reduce inflammation and improve glycemic control, however human data on supplementation and the gut microbiota is equivocal. Processing (i.e., juice concentrate, dried, frozen) may affect the properties of tart cherries, and therefore alter their efficacious health benefits. Therefore, the purpose of this study was to investigate the effect of 30 days of supplementation with Montmorency tart cherry (MTC) in concentrate or freeze-dried form on the gut microbiome and markers of inflammation and glycemic control. Healthy participants with no known disease ( = 58, age: 28 ± 10 y, height: 169.76 ± 8.55 cm, body mass: 72.2 ± 12.9 kg) were randomly allocated to four groups and consumed either concentrate or freeze-dried capsules or their corresponding placebos for 30 days. Venous blood samples were drawn at baseline, day 7, 14, and 30 and analyzed for inflammatory markers TNF-alpha, uric acid, C-reactive protein, and erythrocyte sedimentation rate and glycemic control markers glycated albumin, glucose and insulin. A fecal sample was provided at baseline, day 14 and 30 for microbiome analysis. TNF-alpha was significantly lower at 30 vs. 14 days ( = 0.01), however there was no other significant change in the inflammatory markers. Insulin was not changed over time ( = 0.16) or between groups ( = 0.24), nor was glycated albumin different over time ( = 0.08) or between groups ( = 0.56), however glucose levels increased ( < 0.001) from baseline (4.79 ± 1.00 mmol·L) to 14 days (5.21 ± 1.02 mmol·L) and 30 days (5.61 ± 1.22 mmol·L) but this was no different between groups ( = 0.33). There was no significant change in composition of bacterial phyla, families, or subfamilies for the duration of this study nor was there a change in species richness. These data suggest that 30 days of MTC supplementation does not modulate the gut microbiome, inflammation, or improve glycemic control in a healthy, diverse group of adults. https://clinicaltrials.gov/ct2/show/NCT04467372, identifier: NCT04467372.
酸樱桃具有可能减轻炎症和改善血糖控制的特性，然而关于补充酸樱桃与肠道微生物群的人体数据并不明确。加工（即浓缩汁、干燥、冷冻）可能会影响酸樱桃的特性，从而改变其有效的健康益处。因此，本研究的目的是调查连续30天补充浓缩或冻干形式的蒙特莫伦西酸樱桃（MTC）对肠道微生物群、炎症标志物和血糖控制的影响。将无已知疾病的健康参与者（n = 58，年龄：28±10岁，身高：169.76±8.55厘米，体重：72.2±12.9千克）随机分为四组，连续30天服用浓缩物或冻干胶囊或其相应的安慰剂。在基线、第7天、第14天和第30天采集静脉血样，分析炎症标志物肿瘤坏死因子-α、尿酸、C反应蛋白和红细胞沉降率以及血糖控制标志物糖化白蛋白、葡萄糖和胰岛素。在基线、第14天和第30天提供粪便样本用于微生物群分析。与第14天相比，第30天时肿瘤坏死因子-α显著降低（P = 0.01），然而炎症标志物没有其他显著变化。胰岛素随时间（P = 0.16）或组间（P = 0.24）没有变化，糖化白蛋白随时间（P = 0.08）或组间（P = 0.56）也没有差异，然而葡萄糖水平从基线（4.79±1.00毫摩尔·升）到第14天（5.21±1.02毫摩尔·升）和第30天（5.61±1.22毫摩尔·升）有所升高（P < 0.001），但组间无差异（P = 0.33）。在本研究期间，细菌门、科或亚科的组成没有显著变化，物种丰富度也没有变化。这些数据表明，在健康、多样化的成年人群中，连续30天补充MTC不会调节肠道微生物群、炎症或改善血糖控制。https://clinicaltrials.gov/ct2/show/NCT04467372，标识符：NCT04467372。
